VIMOJ JANARDANAN NAIR

Dr. VIMOJ JANARDANAN NAIR

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

28 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MVMatthew E Volpini
Matthew E Volpini
JSJiheon Song
Jiheon Song
RSRajiv Samant
Rajiv Samant
DMDavid MacDonald
David MacDonald
VNVIMOJ JANARDANAN NAIR
VIMOJ JANARDANAN NAIR
Primary central nervous system lymphoma (PCNSL) is a rare malignancy. Standard of care is upfront high-dose methotrexate (HD-MTX) chemotherapy, while cranial radiation is more commonly used in the salvage setting. In this retrospective study, we aimed to investigate the safety and efficacy of salvage cranial radiation in PCNSL. PCNSL patients who received upfront HD-MTX chemotherapy and salvage cranial radiation after treatment failure between 1995 and 2018 were selected. Radiological response to cranial radiation was assessed as per Response Assessment in Neuro-Oncology Criteria. Twenty one patients were selected (median age 59.9 years), with median follow-up of 19.9 months. Fourteen patients (66.7%) received a boost to the gross tumour volume (GTV). Four patients (19.0%) sustained grade ≥2 treatment-related neurotoxicity post-completion of cranial radiation. Of the 19 patients who had requisite MRI with gadolinium imaging available for Response Assessment in Neuro-Oncology (RANO) criteria assessment, 47.4% achieved complete response, 47.4% achieved partial response, and 5.3% of patients exhibited stable disease. Higher dose to the whole brain (>30 Gy) was associated with higher rate of complete response (63.6%) than lower dose (≤30 Gy, 37.5%), while boost dose to the gross disease was also associated with higher rate of complete response (61.5%) compared with no boost dose (33.3%). Median overall survival was 20.0 months. PCNSL patients who relapsed following upfront chemotherapy showed a high rate of response to salvage cranial radiation, especially in those receiving greater than 30 Gy to the whole brain and boost to gross disease.

1 January 2020 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
VNVIMOJ JANARDANAN NAIR
VIMOJ JANARDANAN NAIR
JCJean Michel Caudrelier
Jean Michel Caudrelier
There is a lack of clear guidelines on optimal radiotherapy dose regimen for elderly breast cancer patients. This review summarizes the current evidence on role of hypofractionated radiotherapy in elderly breast cancer. Also, suggestions have been provided on the best fractionation approaches based on current evidence. Hypofractionated radiotherapy is feasible and well tolerated in elderly breast cancer patients with both early and locally advanced disease. Ultra-hypofractionated regimen seem appropriate for palliation of unresectable primary breast disease and could become a safe approach for adjuvant treatments. Hypofractionated radiotherapy should be considered for treatment of elderly breast cancer for curative intent, as well as for palliation.

26 May 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
JGJoanna Gotfrit
Joanna Gotfrit
RGRachel Goodwin
Rachel Goodwin
Timothy AsmisTimothy Asmis
Timothy Asmis
AHAngela J. Hyde
Angela J. Hyde
TAThierry Alcindor
Thierry Alcindor
Michael VickersMichael Vickers
Michael Vickers
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019 was held in Morell, Prince Edward Island, 19–21 September 2019. Experts in medical oncology, radiation oncology, and surgical oncology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of anal, colorectal, biliary tract, and gastric cancers, including: radiotherapy and systemic therapy for localized and advanced anal cancer; watch and wait strategy for the management of rectal cancer; role of testing for dihydropyrimidine dehydrogenase (DPD) deficiency prior to commencement of fluoropyrimidine therapy; radiotherapy and systemic therapy in the adjuvant and unresectable settings for biliary tract cancer; and radiotherapy and systemic therapy in the perioperative setting for early-stage gastric cancer.

27 June 2022 in Cancer Reports
Verified
Journal Article
Open access
KZKatina Zheng
Katina Zheng
MBMylène Bassal
Mylène Bassal
NMNicholas Mitsakakis
Nicholas Mitsakakis
TCTanita Cepalo
Tanita Cepalo
JHJemila Seid Hamid
Jemila Seid Hamid
DRDhenuka Radhakrishnan
Dhenuka Radhakrishnan
Background: Childhood Hodgkin lymphoma survivors suffer from long‐term effects decades after treatment completion with a prevalence of pulmonary dysfunction of up to 65.2%.Aims: This study explored the early trajectory of pulmonary function in pediatric cancer patients with Hodgkin lymphoma who received pulmonary toxic therapy.Methods and Results: In this single‐center, 20‐year retrospective cohort study, we included patients who were <18 years old at diagnosis of Hodgkin lymphoma between January 1994 and December 2014, and received bleomycin or thoracic radiation. We measured pulmonary function and reported on percent predicted values for forced expiratory volume in 1 s, total lung capacity, and diffusing capacity of the lungs. We used linear mixed models to identify the association of clinical factors with longitudinal changes in lung function at time points before and after treatment completion. Of 80 children who met inclusion criteria, all were treated with bleomycin, and 83.8% received thoracic radiation. More than half (51.2%) of patients had any abnormalities in lung function measures during the study observation period which averaged 24.2 months (±31.1SD). Females, younger age at diagnosis and treatment with radiation were associated with lower lung function measurements at various time points. While the majority of children experienced a recovery of their lung function within 1–2 years after treatment completion, some children with these risk factors did not.Conclusion: Pulmonary function abnormalities begin early in children treated for Hodgkin lymphoma. While the majority of children demonstrate a slow and continuous improvement in lung function back to baseline over time, we recommend routine asymptomatic screening of pulmonary function in certain childhood cancer survivors, particularly females, those diagnosed young and patients who received radiation therapy.

4 September 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
EAEssa Al-Mansor
Essa Al-Mansor
MMMeghan Elizabeth Mahoney
Meghan Elizabeth Mahoney
MCMaxime Chenard-Poirier
Maxime Chenard-Poirier
RRRavi Ramjeesingh
Ravi Ramjeesingh
VNVIMOJ JANARDANAN NAIR
VIMOJ JANARDANAN NAIR
RGRachel Goodwin
Rachel Goodwin
The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023 was held in Quebec City, Quebec 2–4 February 2023. The purpose of the conference was to develop consensus statements on emerging and evolving treatment paradigms. Participants included Canadian medical oncologists, radiation oncologists, pathologists and surgical oncologists from across Ontario, Quebec, and the Atlantic provinces. Consensus statements were developed following rapid review presentations and discussion of available literature. The recommendations proposed here represent the consensus opinions of physicians involved in the care of patients with gastrointestinal malignancies who participated in this meeting.